Analytical Data
-
基因名
FcgBP
- Application
-
别名
FC(GAMMA)BP; IgG Fc Binding Protein; Human Fc Gamma BP; Fcgamma-binding protein antigen
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y6R7
-
表达区间
Cys5176~Ala5344
-
分子量
20kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FcgBP, or Fc gamma binding protein, is a critical component in the immune response, playing a significant role in modulating the activities of antibodies and immune complexes. Understanding FcgBP is vital due to its implications in various diseases, including autoimmune disorders and infections. Research on recombinant FcgBP proteins has gained momentum as these proteins can help elucidate the mechanisms of antibody action and provide insights into potential therapeutic applications. By studying the recombinant form of FcgBP, scientists aim to uncover its binding affinities, structural properties, and interactions with various Fc receptors. This research is invaluable for developing targeted therapies that can enhance immune responses or inhibit pathologies driven by dysregulated immune functions. Recombining FcgBP with other immunotherapeutic agents may also lead to innovative strategies for treating conditions characterized by excessive inflammation or diminished immune efficacy. Overall, the exploration of recombinant FcgBP proteins stands at the intersection of immunology and therapeutic development, offering a promising avenue for advancing our understanding of immune system dynamics and enhancing clinical outcomes in various health conditions.
